Open AccessBilateral vs Unilateral Hypoglossal Nerve Stimulation in Patients With Obstructive Sleep Apnea
Author(s) -
Heiser Clemens,
Sommer J. Ulrich,
Hofauer Benedikt,
Vries Nico,
Ravesloot Madeline JL,
Vanderveken Olivier M.,
Jira Daniel
Publication year - 2022
Publication title -
oto open
Language(s) - English
Resource type - Journals
ISSN - 2473-974X
DOI - 10.1177/2473974x221109794
Subject(s) - hypoglossal nerve , epworth sleepiness scale , medicine , obstructive sleep apnea , anesthesia , polysomnography , body mass index , apnea , stimulation , tongue , pathology
Objective Unilateral hypoglossal nerve stimulation (uniHNS) is an effective treatment for obstructive sleep apnea. Bilateral hypoglossal nerve stimulation (biHNS) is a novel therapeutic option and a different approach to hypoglossal nerve stimulation. The aim of this study was to analyze the clinical outcome of the first 10 biHNS cases vs the first 10 uniHNS cases ever implanted. Study Design Prospective data analysis. Setting International multicenter comparative clinical trial. Methods The first 10 patients in 2020 who received a biHNS device (Genio System; Nyxoah) and the first 10 patients in 2014 who received a uniHNS system (Inspire II; Inspire Medical Systems) were included. Treatment outcome was evaluated at 3 months after surgery. Data collection included demographics, apnea hypopnea index (AHI), oxygen saturation and desaturation index, Epworth Sleepiness Scale, and adverse events. Results The mean ± SD age was 52.1 ± 9.6 years (biHNS) and 58.3 ± 8.6 years (uniHNS). The mean body mass index was 26.4 ± 5.6 kg/m 2 (biHNS) and 26.2 ± 2.2 kg/m 2 (uniHNS). The mean preimplantation AHI (biHNS, 39.9 ± 14.8/h; uniHNS, 32.2 ± 11.0/h) decreased in both groups after 3 months (biHNS, 19.2 ± 14.0/h, P =. 008; uniHNS, 13.1 ± 16.8/h, P =. 037) with no significant difference between groups ( P =. 720). The mean preimplantation Epworth Sleepiness Scale (biHNS, 11.8 ± 6.2; uniHNS, 11.1 ± 4.9) decreased as well after 3 months (biHNS, 9.4 ± 6.3; uniHNS, 6.0 ± 5.0). Conclusion Preliminary postmarket data suggest that biHNS may be as safe and effective as uniHNS. Long‐term follow‐up in a larger sample size is required to assess the stability of biHNS.